Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Feasibility study protocol for the evaluation of home blood pressure in patients receiving angiogenesis inhibitor therapy: a multicenter observational study

Hypertension Research (2026)Cite this article

Abstract

Elevated blood pressure is frequently observed during cancer treatment with vascular endothelial growth factor inhibitors, reflecting either a treatment-emergent adverse event or pharmacological effect. Appropriate blood pressure management is critical in minimizing cardiovascular risk and prevent treatment interruption. Although home blood pressure monitoring is recommended to detect masked or white-coat hypertension, longitudinal data on home blood pressure trajectories during therapy remain limited. This multicenter observational pilot study aims to evaluate the association between clinic and home blood pressure in patients with malignant tumors receiving vascular endothelial growth factor inhibitors, and to assess factors associated with blood pressure variability and the feasibility of home monitoring during therapy. Approximately 50 participants are being enrolled. Home blood pressure is measured twice daily throughout the treatment period, and clinical, laboratory, and treatment-related data and patient-reported data are collected at baseline, during therapy, and at follow-up. The primary outcome is the difference between clinic and home blood pressures at multiple time points during and after vascular endothelial growth factor inhibitor therapy. Blood pressure phenotypes will be classified according to clinic and home blood pressure thresholds, and their clinical characteristics will be compared. Longitudinal trajectory of home blood pressure will be assessed to explore patterns associated with clinical outcomes. This study will clarify the relationship between clinic and home blood pressure, explore factors influencing blood pressure variability, and provide preliminary evidence on the feasibility and clinical value of home blood pressure monitoring in patients receiving angiogenesis inhibitor therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889–97.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens. 2013;2013:379252.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gudsoorkar P, Ruf R, Adnani H, Safdar K, Sparks MA. Onco-hypertension: an emerging specialty. Adv Chronic Kidney Dis. 2021;28:477–89 e1.

    Article  PubMed  Google Scholar 

  4. Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, et al. New concept of onco-hypertension and future perspectives. Hypertension. 2021;77:16–27.

    Article  PubMed  Google Scholar 

  5. Pandey S, Kalaria A, Jhaveri KD, Herrmann SM, Kim AS. Management of hypertension in patients with cancer: challenges and considerations. Clin Kidney J. 2023;16:2336–48.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80:e46–e57.

    Article  PubMed  Google Scholar 

  7. Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H, et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 2005;111:796–803.

    Article  PubMed  Google Scholar 

  8. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652–8.

    Article  PubMed  Google Scholar 

  9. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, et al. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011;58:85–92.

    Article  PubMed  Google Scholar 

  10. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71:e1–e8.

    Article  PubMed  Google Scholar 

  11. Si F, Ma X, Liu Q, Yu J. Reviewing the path to balance: mechanisms and management of hypertension associated with targeting vascular endothelium in cancer therapy. Hypertens Res. 2025;48:1034–47.

    Article  PubMed  Google Scholar 

  12. Costa LJ, Varella PC, Del Giglio A. White coat effect in breast cancer patients undergoing chemotherapy. Eur J Cancer Care (Engl). 2003;12:372–3.

    PubMed  Google Scholar 

  13. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95–7.

    Article  PubMed  Google Scholar 

  14. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011;16:1325–32.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer patients and survivors: epidemiology, diagnosis, and management. JACC CardioOncol. 2019;1:238–51.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Maruhashi T, Tatsumi Y, Satoh M, Kobayashi Y, Ogoyama Y, Sakima A, et al. Updated meta-analysis for antihypertensive treatment guided by home blood pressure compared to treatment based on office blood pressure: systematic review. Hypertens Res. 2025;48:1839–45.

    Article  PubMed  Google Scholar 

  17. Satoh M, Tatsumi Y, Nakayama S, Shinohara Y, Kawazoe M, Nozato Y, et al. Self-measurement of blood pressure at home using a cuff device for change in blood pressure levels: systematic review and meta-analysis. Hypertens Res. 2025;48:574–91.

    Article  PubMed  Google Scholar 

  18. Committee of the Japanese Society of Hypertension Guidelines. The Japanese Society of Hypertension Guidelines for the Management of Elevated Blood Pressure and Hypertension 2025 (JSH2025). Tokyo, 2025.

  19. Rao VU, Reeves DJ, Chugh AR, O’Quinn R, Fradley MG, Raghavendra M, et al. Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2693–716.

    Article  PubMed  Google Scholar 

  20. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227–30.

    Article  PubMed  Google Scholar 

  21. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, et al. Treatment-related hypertension as a pharmacodynamic biomarker for the efficacy of bevacizumab in advanced pancreas cancer: a pooled analysis of 4 prospective trials of gemcitabine-based therapy with bevacizumab. Am J Clin Oncol. 2016;39:614–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Shibata K, Akasaki Y, Tokushige A, Nitta M, Kawasoe S, Kubozono T, et al. Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis. Hypertens Res. 2025;48:1542–53.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Zhu X, Wu S. Risks and management of hypertension in cancer patients undergoing targeted therapy: a review. Clin Hypertens. 2022;28:14.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763–73.

    Article  PubMed  PubMed Central  Google Scholar 

  25. van Dorst DCH, Kabadayi S, Oomen-de Hoop E, Danser AHJ, Mathijssen RHJ, Versmissen J. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study. J Am Heart Assoc. 2023;12:e028050.

    Article  PubMed  Google Scholar 

  26. Common Toxicity Criteria Program. Common Toxicity Criteria, Version2.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed 10 Oct 2024.

  27. Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for designing and evaluating feasibility pilot studies. Med Care. 2022;60:95–103.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Huang RS, Chen D, Benour A, Cortez R, Mihalache A, Johnny C, et al. Patient-reported outcomes as prognostic indicators for overall survival in cancer: a systematic review and meta-analysis. JAMA Oncol. 2025;11:1303–12.

  29. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634–46.

    Article  PubMed  Google Scholar 

  30. Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16:97–103.

    Article  PubMed  Google Scholar 

  31. Ohkubo T, Obara T, Funahashi J, Kikuya M, Asayama K, Metoki H, et al. Control of blood pressure as measured at home and office, and comparison with physicians’ assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res. 2004;27:755–63.

    Article  PubMed  Google Scholar 

  32. Plummer C, Michael A, Shaikh G, Stewart M, Buckley L, Miles T, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer. 2019;121:109–16.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Suzuki Y, Kaneko H, Okada A, Fujiu K, Takeda N, Morita H, et al. Risk of cancer history in cardiovascular disease among individuals with hypertension. Hypertens Res. 2024;47:1871–80.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shiga University of Medical Science, NCD Epidemiology Research Center, Shiga, Japan

    Kaori Kitaoka

  2. Section of Research Collaboration and Partnership, Center for Private-Public-Academic Collaboration Research, National Institutes of Biomedical Innovation, Health and Nutrition, Settu, Japan

    Kaori Kitaoka

  3. Department of Medicine, Tokyo Women’s Medical University Adachi Medical Center, Tokyo, Japan

    Satoshi Morimoto

  4. Division of Hormonal Medicine and Bioregulatory Science, Department of Medicine, Tokyo Women’s Medical University, Tokyo, Japan

    Satoshi Morimoto

  5. Department of Cardiology, Yokohama City University School of Medicine, Yokohama, Japan

    Shintaro Minegishi

  6. Division of Onco-Cardiology, Miyagi Cancer Center, Miyagi, Japan

    Hiroshi Kato

  7. Department of Cardiology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

    Yasuyuki Kitahara

  8. Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan

    Wataru Shioyama

  9. Department of General Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

    Taro Shiga

  10. Department of Onco-Cardiology/Cardiovascular Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

    Taro Shiga

  11. Department of Cardiology, National Cancer Center Hospital East, Kashiwa, Japan

    Kazuko Tajiri

  12. Tsukuba Life Science Innovation Program (T-LSI), School of Integrative and Global Majors (SIGMA), University of Tsukuba, Tsukuba, Japan

    Kazuko Tajiri

  13. Department of General Internal Medicine, National Cancer Center Hospital, Tokyo, Japan

    Masaaki Shoji

  14. Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

    Mitsuhiro Fukata

  15. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Hiroshi Akazawa

  16. Osaka Center for Cancer and Cardiovascular Disease Prevention, Osaka, Japan

    Mikio Mukai

  17. Department of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan

    Yuichiro Yano

  18. Artificial Intelligence Incubation Farm (AIF), Juntendo University Faculty of Medicine, Tokyo, Japan

    Yuichiro Yano

  19. Department of Family Medicine and Community Health, Duke University, Duke, NC, USA

    Yuichiro Yano

  20. Department of Cardiovascular Medicine, Saga University, Saga, Japan

    Koichi Node

  21. Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Akira Nishiyama

Authors
  1. Kaori Kitaoka
    View author publications

    Search author on:PubMed Google Scholar

  2. Satoshi Morimoto
    View author publications

    Search author on:PubMed Google Scholar

  3. Shintaro Minegishi
    View author publications

    Search author on:PubMed Google Scholar

  4. Hiroshi Kato
    View author publications

    Search author on:PubMed Google Scholar

  5. Yasuyuki Kitahara
    View author publications

    Search author on:PubMed Google Scholar

  6. Wataru Shioyama
    View author publications

    Search author on:PubMed Google Scholar

  7. Taro Shiga
    View author publications

    Search author on:PubMed Google Scholar

  8. Kazuko Tajiri
    View author publications

    Search author on:PubMed Google Scholar

  9. Masaaki Shoji
    View author publications

    Search author on:PubMed Google Scholar

  10. Mitsuhiro Fukata
    View author publications

    Search author on:PubMed Google Scholar

  11. Hiroshi Akazawa
    View author publications

    Search author on:PubMed Google Scholar

  12. Mikio Mukai
    View author publications

    Search author on:PubMed Google Scholar

  13. Yuichiro Yano
    View author publications

    Search author on:PubMed Google Scholar

  14. Koichi Node
    View author publications

    Search author on:PubMed Google Scholar

  15. Akira Nishiyama
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Morimoto.

Ethics declarations

Conflict of interest

M.M. has received speaking honoraria from Daiichi Sankyo, Ferring Pharmaceuticals and Janssen Pharmaceutical.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kitaoka, K., Morimoto, S., Minegishi, S. et al. Feasibility study protocol for the evaluation of home blood pressure in patients receiving angiogenesis inhibitor therapy: a multicenter observational study. Hypertens Res (2026). https://doi.org/10.1038/s41440-025-02524-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41440-025-02524-1

Keywords

Search

Advanced search

Quick links